Project Grant K01CA285946
- This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $495,036 Project Grant awarded September 14, 2025, by the National Institute for Minority Health and Health Disparities under the Minority Health and Health Disparities Research program (CFDA 93.307) to support cervical cancer screening initiatives in rural North Carolina. The project, titled "Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North...
- This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $702,461 Project Grant effective June 1, 2026, through May 31, 2031, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the impact of a novel educational intervention designed to improve timely colposcopy follow-up and treatment among high-risk populations. The award supports a hybrid type 1A implementation-effectiveness trial testing the...
- Federal Project Grant Award Summary The National Institute on Minority Health and Health Disparities (NIMHD) awarded $518,267 to The Trustees of Columbia University in the City of New York on September 24, 2025, under the Minority Health and Health Disparities Research program (CFDA 93.307) to conduct a two-phase K99/R00 research project examining the relationship between life-course stressors, mitochondrial dysfunction, and preterm birth (PTB) risk among Black women. During the K99 phase,...
- This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded a $1.41 million Project Grant to the University of Colorado-Denver, with performance running from September 1, 2025, through May 31, 2030. This ancillary study investigates the impact of pregnancy microbiomes on maternal and child cardiovascular health outcomes in a racially and ethnically diverse cohort. The research addresses a critical public...
- Grant Award Summary Mucommune LLC received a $310,136 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) with an award date of August 21, 2025, and completion date of July 31, 2027. The project focuses on engineering an intravaginal ring (IVR) that releases lactic acid for the treatment and prevention of bacterial vaginosis (BV), a prevalent vaginal infection that is highly prone to...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a Project Grant of $195,640 (awarded September 17, 2025) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a five-year research career development initiative examining the vaginal microbiome and bacterial vaginosis (BV) treatment outcomes. The research will identify subpopulations that demonstrate enhanced therapeutic response to...
- Grant Award Summary The National Institute on Minority Health and Health Disparities (NIMHD) awarded $1.25 million under the Minority Health and Health Disparities Research program (CFDA 93.307) to SUNY Downstate Health Sciences University for a Project Grant spanning May 6, 2026, through November 30, 2030. The award funds "Our Family, Our Voices" (OFOV), an efficacy trial of a community-driven intervention designed to optimize HIV prevention and care outcomes for Black sexual and...
ELUCIDATING THE ROLE OF THE VAGINAL MICROBIOME IN RACIAL DISPARITIES IN PRECANCEROUS CERVICAL LESIONS: A MULTI-LEVEL STUDY - PROJECT SUMMARY DESPITE PROGRESS IN HUMAN PAPILLOMAVIRUS (HPV) VACCINATION UPTAKE, ABOUT THREE MILLION WOMEN ARE STILL DIAGNOSED WITH PRECANCEROUS CERVICAL LESIONS EACH YEAR IN THE US. MOST SPONTANEOUSLY REGRESS, BUT YEARLY FOLLOW UP AND INVASIVE PROPHYLACTIC CARE (E.G., ENDOCERVICAL CURETTAGE AND CERVICAL BIOPSY) IS STILL REQUIRED AS IT IS NOT CLEAR WHICH MAY PROGRESS TO CERVICAL CANCER. SINCE BLACK WOMEN HAVE MORE PERSISTENT HPV INFECTIONS AND PRECANCEROUS LESIONS, AS WELL AS A HIGHER INCIDENCE OF CERVICAL CANCER THAN WHITE WOMEN, THEY ARE DISPROPORTIONATELY IMPACTED BY THESE INVASIVE PROPHYLACTIC PROCEDURES AND THEIR SEQUELAE (E.G., PAIN, BLEEDING, SCARRING, INFERTILITY, FUTURE MISCARRIAGES, AND PRETERM BIRTHS). THE VAGINAL MICROBIOME (VMB) HAS BEEN IMPLICATED IN SUSTAINING HPV INFECTION AND DEVELOPMENT OF PRECANCEROUS LESIONS. HPV-POSITIVE WOMEN, WOMEN WITH PRECANCEROUS LESIONS, AND BLACK WOMEN ARE MORE LIKELY TO HAVE A SUBOPTIMAL VMB WITH HIGH TAXONOMIC DIVERSITY WITH DEPLETION OF LACTOBACILLUS SPP. (BOTH FEATURES OF VAGINAL INFLAMMATION AND DYSBIOSIS) AND ARE ALSO ASSOCIATED WITH WORSE PROGNOSIS FOR PRECANCEROUS LESIONS. MY PRELIMINARY DATA SHOWS THAT AN OPTIMAL, LACTOBACILLUS PREDOMINANT VMB IS PROTECTIVE AGAINST THE RISK OF A PRECANCEROUS CERVICAL LESION FOR WHITE BUT NOT BLACK WOMEN. SINCE THE VMB IS SUSCEPTIBLE TO THE HOST MICRO AND MACRO ENVIRONMENTS, IT IS PLAUSIBLE THAT THESE DIFFERENCES OVERRIDE THE PROTECTIVE EFFECT OF THE VMB IN BLACK WOMEN. AT THE MICRO LEVEL, DIFFERENCES IN SPECIES-SPECIFIC METABOLIC PROFILES MIGHT BE CONTRIBUTING TO LESION PROGNOSIS BY DISTURBING VAGINAL HOMEOSTASIS. AT THE MACRO LEVEL, PSYCHOLOGICAL STRESS, WHICH IS DISPROPORTIONATELY EXPERIENCED BY BLACK WOMEN MAY BE INFLUENCING THE VMB THROUGH A CORTISOL PATHWAY WHICH HAS BEEN BIOLOGICALLY IMPLICATED WITH VMB DYNAMICS AND KNOWN TO BE DYSREGULATED IN BLACK WOMEN IN RESPONSE TO STRESS. IN THIS K01 APPLICATION, I WILL TEST THE HYPOTHESIS THAT RACIAL DIFFERENCES IN DAILY EXPERIENCES OF STRESS AND RESPECTIVE CORTISOL RESPONSE RESULT IN VMB CHANGES THAT INFLUENCE DIFFERENTIAL PRECANCEROUS LESION REGRESSION BY RACE. I WILL MEASURE VMB CHANGES AND PSYCHOLOGICAL (ECOLOGICAL MOMENTARY ASSESSMENTS), AND PHYSIOLOGICAL STRESS (SALIVARY CORTISOL) AMONG 75 BLACK AND 75 WHITE WOMEN DIAGNOSED WITH A CERVICAL LESION, ASSESSED DURING THE CRITICAL TIME BETWEEN THEIR ROUTINE PAP SCREEN AND ABNORMAL FOLLOW-UP. THE PROPOSED MENTORSHIP, TRAINING AND RESEARCH WILL GIVE ME CRITICAL SKILLS IN BIOINFORMATICS, STATISTICAL AND MOLECULAR BIOLOGY TO INTERROGATE PLAUSIBLE MECHANISMS THROUGH WHICH THE VMB MIGHT UNDERLIE RACIALLY DIFFERENTIAL ETIOLOGIES FOR PRE-CANCEROUS CERVICAL LESIONS. THE TRAINING DESCRIBED IN THIS PROPOSAL WILL PREPARE ME TO BECOME AN INDEPENDENT TRANSLATIONAL INVESTIGATOR LEADING TO THE IDENTIFICATION OF PRACTICAL SOLUTIONS TO THE REDUCTION OF CANCER OUTCOME DISPARITIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $183.7k | 6/30/26 | ||
| Not listed | $183.7k | 9/15/25 | ||
| Not listed | $183.7k | 6/14/24 |